New triple therapy takes on tough colorectal cancer

NCT ID NCT07550088

Recruiting now Disease control Sponsor: Darren Sigal, MD Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Aug 11, 2026 · Updated 2 times

Summary

This phase II trial tests whether a combination of three drugs—balstilimab, botensilimab, and agenT-797—can shrink tumors in adults with a specific type of advanced colorectal cancer that has spread to the liver. All 17 participants will receive the treatment, and researchers will track tumor response and side effects. The goal is to find a new option for patients who have already tried standard chemotherapy.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: balstilimab, botensilimab, and agenT-797 (a type of immune cell therapy)
What this could lead to: If this works, it could offer a new treatment option for people with a hard-to-treat form of colorectal cancer that has spread to the liver.
What could go wrong: This is a small, early-phase trial with only 17 participants and no comparison group. The combination may cause significant side effects, including immune reactions, and may not shrink tumors in most patients.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for COLORECTAL CANCER METASTATIC are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

colorectal cancer colorectal neoplasm

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

COLORECTAL CANCER METASTATIC

Contacts and locations

Locations

Scripps Clinic Torrey Pines
RECRUITING

La Jolla, California, 92037, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.